

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LANSEN PHARMACEUTICAL HOLDINGS LIMITED

朗生醫藥控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 503)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 15 JUNE 2018

The Board is pleased to announce that all the resolutions proposed at the AGM held on 15 June 2018 were duly passed.

The board of directors (the “**Board**”) of Lanssen Pharmaceutical Holdings Limited (the “**Company**”) is pleased to announce that at the annual general meeting of the Company held on 15 June 2018 (the “**AGM**”), all the resolutions proposed were duly passed by way of poll voting. The poll results are as follows:

Ordinary Resolutions		Number of Votes (Approximate %) ^{(Note(a))}	
		For	Against
1.	To receive and consider the audited consolidated financial statements, the report of the directors and the independent auditor’s report thereon for the year ended 31 December 2017.	210,608,500 (100.00%)	0 (0.00%)
2.	To approve the recommended final dividend of HK3.58 cents per share of US\$0.01 each in the capital of the Company out of the Company’s share premium account for the year ended 31 December 2017.	210,606,500 (99.99%)	2,000 (0.01%)
3.	(i) To re-elect Mr. Chen Li as an executive managing Director of the Company.	210,604,500 (99.99%)	2,000 (0.01%)

Ordinary Resolutions		Number of Votes (%) ^{(Note(a))}	
		For	Against
3.	(ii) To re-elect Mr. Hou Song as an executive Director of the Company.	210,604,500 (99.99%)	2,000 (0.01%)
	(iii) To re-elect Ms. Liu Xuezi as a non-executive Director of the Company.	210,604,500 (99.99%)	2,000 (0.01%)
	(iv) To authorise the Board to fix the remuneration of directors of the Company.	210,603,500 (99.99%)	3,000 (0.01%)
4.	To re-appoint BDO Limited as auditor of the Company and to authorise the Board to fix its remuneration.	210,604,500 (99.99%)	2,000 (0.01%)
5.	(A) To grant a general mandate to the directors of the Company to allot, issue and deal with additional shares not exceeding 20% of the issued share capital of the Company as at the date of passing this resolution.	209,970,500 (99.70%)	638,000 (0.30%)
	(B) To grant a general mandate to the directors of the Company to repurchase shares not exceeding 10% of the issued share capital of the Company as at the date of passing this resolution.	210,608,500 (100.00%)	0 (0.00%)
	(C) To extend the general mandate granted to the directors of the Company to allot, issue and deal with additional shares in the share capital of the Company by an amount not exceeding the amount of the shares repurchased by the Company.	209,970,500 (99.70%)	638,000 (0.30%)

Notes:

- (a) The number and percentage of votes are based on the total number of shares of the Company voted by the shareholders of the Company at the AGM in person or by proxy.
- (b) As more than 50% of the votes were cast in favour of the resolutions, all the resolutions were duly passed as ordinary resolutions.
- (c) The total number of shares of the Company in issue as at the date of AGM: 415,000,000 shares.
- (d) The total number of shares of the Company entitling the holder to attend and vote for or against the resolutions at the AGM: 415,000,000 shares.
- (e) The total number of shares of the Company entitling the holder to attend and vote only against the resolutions at the AGM: Nil.

- (f) There were no restrictions on any shareholders of the Company to cast votes on any of the proposed resolutions at the AGM.
- (g) None of the shareholders of the Company have stated their intention in the Company's circular dated 19 April 2018 to vote against or to abstain from voting on any of the resolutions at the AGM.
- (h) The Company's Branch Share Registrar in Hong Kong, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

By order of the Board
Lansen Pharmaceutical Holdings Limited
Wu Zhen Tao
Chairman

Hong Kong, 15 June 2018

As at the date of this announcement, the executive managing Director is Mr. Chen Li; the executive Director is Mr. Hou Song; the non-executive Directors are Mr. Wu Zhen Tao, Mr. Lee Jin Yi, Mr. Stephen Burnau Hunt and Ms. Liu Xuezi; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Tang Chiu Ping, Raymond and Mr. Fritz Heinrich Horlacher